L-arginine and vitamin D

novel adjunctive immunotherapies in tuberculosis

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Worsening drug resistance and the need for prolonged treatment in tuberculosis (TB) require innovative solutions including investigation of inexpensive, safe adjunctive immunotherapies. L-arginine, the precursor of nitric oxide, and vitamin D recently have elucidated mycobactericidal and immunomodulatory actions against TB and are deficient in people with TB. We review the potential of these agents as adjunctive TB immunotherapies and explore how comparative clinical trials might help clarify their relative importance in the human TB immune response. By enhancing mycobacterial killing in macrophages, L-arginine and vitamin D might have the potential to enable shorter duration of treatment, reduced infectivity and improved response in drug-resistant TB. � 2008 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)336-344
Number of pages9
JournalTrends in Microbiology
Volume16
Issue number7
Publication statusPublished - 2008

Fingerprint

Vitamin D
Immunotherapy
Arginine
Tuberculosis
Multidrug-Resistant Tuberculosis
Drug Resistance
Nitric Oxide
Macrophages
Clinical Trials
Therapeutics

Cite this

@article{6e4ca7ca93bf4fbd8baf84f2b132cc09,
title = "L-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis",
abstract = "Worsening drug resistance and the need for prolonged treatment in tuberculosis (TB) require innovative solutions including investigation of inexpensive, safe adjunctive immunotherapies. L-arginine, the precursor of nitric oxide, and vitamin D recently have elucidated mycobactericidal and immunomodulatory actions against TB and are deficient in people with TB. We review the potential of these agents as adjunctive TB immunotherapies and explore how comparative clinical trials might help clarify their relative importance in the human TB immune response. By enhancing mycobacterial killing in macrophages, L-arginine and vitamin D might have the potential to enable shorter duration of treatment, reduced infectivity and improved response in drug-resistant TB. � 2008 Elsevier Ltd. All rights reserved.",
keywords = "arginine, bisphosphonic acid derivative, cod liver oil, colecalciferol, nitric oxide, vitamin D, bactericidal activity, clinical trial, drug mechanism, gene expression, human, hypercalcemia, immune response, immunomodulation, immunotherapy, low drug dose, Mycobacterium tuberculosis, nonhuman, priority journal, review, treatment duration, tuberculosis, Adjuvants, Immunologic, Arginine, Cell Line, Humans, Immunotherapy, Macrophage Activation, Macrophages, Tuberculosis, Tuberculosis, Pulmonary, Vitamin D",
author = "Anna Ralph and P KELLY and Nicholas Anstey",
year = "2008",
language = "English",
volume = "16",
pages = "336--344",
journal = "Trends in Microbiology",
issn = "0966-842X",
publisher = "Elsevier",
number = "7",

}

L-arginine and vitamin D : novel adjunctive immunotherapies in tuberculosis. / Ralph, Anna; KELLY, P; Anstey, Nicholas.

In: Trends in Microbiology, Vol. 16, No. 7, 2008, p. 336-344.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - L-arginine and vitamin D

T2 - novel adjunctive immunotherapies in tuberculosis

AU - Ralph, Anna

AU - KELLY, P

AU - Anstey, Nicholas

PY - 2008

Y1 - 2008

N2 - Worsening drug resistance and the need for prolonged treatment in tuberculosis (TB) require innovative solutions including investigation of inexpensive, safe adjunctive immunotherapies. L-arginine, the precursor of nitric oxide, and vitamin D recently have elucidated mycobactericidal and immunomodulatory actions against TB and are deficient in people with TB. We review the potential of these agents as adjunctive TB immunotherapies and explore how comparative clinical trials might help clarify their relative importance in the human TB immune response. By enhancing mycobacterial killing in macrophages, L-arginine and vitamin D might have the potential to enable shorter duration of treatment, reduced infectivity and improved response in drug-resistant TB. � 2008 Elsevier Ltd. All rights reserved.

AB - Worsening drug resistance and the need for prolonged treatment in tuberculosis (TB) require innovative solutions including investigation of inexpensive, safe adjunctive immunotherapies. L-arginine, the precursor of nitric oxide, and vitamin D recently have elucidated mycobactericidal and immunomodulatory actions against TB and are deficient in people with TB. We review the potential of these agents as adjunctive TB immunotherapies and explore how comparative clinical trials might help clarify their relative importance in the human TB immune response. By enhancing mycobacterial killing in macrophages, L-arginine and vitamin D might have the potential to enable shorter duration of treatment, reduced infectivity and improved response in drug-resistant TB. � 2008 Elsevier Ltd. All rights reserved.

KW - arginine

KW - bisphosphonic acid derivative

KW - cod liver oil

KW - colecalciferol

KW - nitric oxide

KW - vitamin D

KW - bactericidal activity

KW - clinical trial

KW - drug mechanism

KW - gene expression

KW - human

KW - hypercalcemia

KW - immune response

KW - immunomodulation

KW - immunotherapy

KW - low drug dose

KW - Mycobacterium tuberculosis

KW - nonhuman

KW - priority journal

KW - review

KW - treatment duration

KW - tuberculosis

KW - Adjuvants, Immunologic

KW - Arginine

KW - Cell Line

KW - Humans

KW - Immunotherapy

KW - Macrophage Activation

KW - Macrophages

KW - Tuberculosis

KW - Tuberculosis, Pulmonary

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=46049098541&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 336

EP - 344

JO - Trends in Microbiology

JF - Trends in Microbiology

SN - 0966-842X

IS - 7

ER -